GlassScriptPhysician profile
Bhavyata Patel
NPI 1548789506
$3,639.25
in general payments reported to CMS, 2019-2025
20 companies · $915 in 2025
The $915 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.83 · 2021: $265 · 2022: $457 · 2023: $1,101 · 2024: $872 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,129.27 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $562.59 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $387.54 | 2020-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $218.22 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $197.76 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $193.34 | 2022-2025 | |
| Pfizer INC. | $161.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $130.34 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $119.42 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.73 | 2024-2025 | Ofev, Jardiance |
| Amneal Pharmaceuticals LLC | $87.75 | 2023-2025 | Unithroid |
| Dexcom, INC. | $84.72 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $67.40 | 2023-2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $63.22 | 2023-2025 | Ragwitek, Grastek, Odactra |
| Merck Sharp & Dohme LLC | $36.23 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.22 | 2021 | |
| Intra-Sana Laboratories | $17.95 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Hologic Sales and Service, LLC | $17.13 | 2023 | Aptima |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2024 | Opsumit, Uptravi |
| Qiagen, LLC | $15.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavyata Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.